Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Act1, scene brain: astrocytes play a lead role.

Literature DB >> 20346771

Act1, scene brain: astrocytes play a lead role.

Jane M Rodgers¹, Liang Zhou, Stephen D Miller.

Abstract

Interleukin-17 (IL-17) is crucial for the progression of experimental autoimmune encephalomyelitis. In this issue of Immunity, Kang et al. (2010) report that neuroectoderm-derived astrocytes are the critical cellular element that responds to IL-17.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20346771 PMCID： PMC2858315 DOI： 10.1016/j.immuni.2010.03.009

Source DB: PubMed Journal: Immunity ISSN： 1074-7613 Impact factor: 31.745

10 in total

1. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

Authors: T A Yednock; C Cannon; L C Fritz; F Sanchez-Madrid; L Steinman; N Karin
Journal: Nature Date: 1992-03-05 Impact factor: 49.962

2. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

Authors: Samantha L Bailey; Bettina Schreiner; Eileen J McMahon; Stephen D Miller
Journal: Nat Immunol Date: 2007-01-07 Impact factor: 25.606

3. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease.

Authors: Youcun Qian; Caini Liu; Justin Hartupee; Cengiz Zubeyir Altuntas; Muhammet Fatih Gulen; Daniel Jane-Wit; Jianhua Xiao; Yi Lu; Natalia Giltiay; Jinbo Liu; Tomasz Kordula; Qi-Wei Zhang; Bruce Vallance; Shadi Swaidani; Mark Aronica; Vincent K Tuohy; Thomas Hamilton; Xiaoxia Li
Journal: Nat Immunol Date: 2007-02-04 Impact factor: 25.606

4. IL-17 enhances chemokine gene expression through mRNA stabilization.

Authors: Justin Hartupee; Caini Liu; Michael Novotny; Xiaoxia Li; Thomas Hamilton
Journal: J Immunol Date: 2007-09-15 Impact factor: 5.422

5. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor.

Authors: Seon Hee Chang; Heon Park; Chen Dong
Journal: J Biol Chem Date: 2006-10-11 Impact factor: 5.157

6. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis.

Authors: Zizhen Kang; Cengiz Zubeyir Altuntas; Muhammet Fatih Gulen; Caini Liu; Natalia Giltiay; Hongwei Qin; Liping Liu; Wen Qian; Richard M Ransohoff; Cornelia Bergmann; Stephen Stohlman; Vincent K Tuohy; Xiaoxia Li
Journal: Immunity Date: 2010-03-18 Impact factor: 31.745

7. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis.

Authors: Stephen Mark Tompkins; Josette Padilla; Mauro C Dal Canto; Jenny P-Y Ting; Luc Van Kaer; Stephen D Miller
Journal: J Immunol Date: 2002-04-15 Impact factor: 5.422

8. Act1, a negative regulator in CD40- and BAFF-mediated B cell survival.

Authors: Youcun Qian; Jinzhong Qin; Grace Cui; Mayumi Naramura; E Charles Snow; Carl F Ware; Robert L Fairchild; Sidne A Omori; Robert C Rickert; Martin Scott; Brian L Kotzin; Xiaoxia Li
Journal: Immunity Date: 2004-10 Impact factor: 31.745

Review 9. Structure and signalling in the IL-17 receptor family.

Authors: Sarah L Gaffen
Journal: Nat Rev Immunol Date: 2009-07-03 Impact factor: 53.106

Review 10. Nestin in central nervous system cells.

Authors: A V Gilyarov
Journal: Neurosci Behav Physiol Date: 2008-02

10 in total

Review 1. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors: Jerold Chun; Volker Brinkmann
Journal: Discov Med Date: 2011-09 Impact factor: 2.970

2. IL-17A induces MIP-1α expression in primary astrocytes via Src/MAPK/PI3K/NF-kB pathways: implications for multiple sclerosis.

Authors: Hongwei Yi; Ying Bai; Xinjian Zhu; Lin Lin; Lei Zhao; Xiaodong Wu; Shilpa Buch; Longxin Wang; Jie Chao; Honghong Yao
Journal: J Neuroimmune Pharmacol Date: 2014-07-03 Impact factor: 4.147

3. TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development.

Authors: Carlo Perricone; Cinzia Ciccacci; Fulvia Ceccarelli; Davide Di Fusco; Francesca Romana Spinelli; Enrica Cipriano; Giuseppe Novelli; Guido Valesini; Fabrizio Conti; Paola Borgiani
Journal: Immunogenetics Date: 2013-07-09 Impact factor: 2.846

4. Control of IL-17 receptor signaling and tissue inflammation by the p38α-MKP-1 signaling axis in a mouse model of multiple sclerosis.

Authors: Gonghua Huang; Yanyan Wang; Peter Vogel; Hongbo Chi
Journal: Sci Signal Date: 2015-03-03 Impact factor: 8.192

Review 5. Maternal IL-17A in autism.

Authors: Helen Wong; Charles Hoeffer
Journal: Exp Neurol Date: 2017-04-25 Impact factor: 5.330

Review 10. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?

Authors: Katherine A Buzzard; Simon A Broadley; Helmut Butzkueven
Journal: Int J Mol Sci Date: 2012-10-04 Impact factor: 5.923

10 in total

Act1, scene brain: astrocytes play a lead role.

1. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

2. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

3. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease.

4. IL-17 enhances chemokine gene expression through mRNA stabilization.

5. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor.

6. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis.

7. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis.

8. Act1, a negative regulator in CD40- and BAFF-mediated B cell survival.

Review 9. Structure and signalling in the IL-17 receptor family.

Review 10. Nestin in central nervous system cells.

Review 1. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

2. IL-17A induces MIP-1α expression in primary astrocytes via Src/MAPK/PI3K/NF-kB pathways: implications for multiple sclerosis.

3. TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development.

4. Control of IL-17 receptor signaling and tissue inflammation by the p38α-MKP-1 signaling axis in a mouse model of multiple sclerosis.

Review 5. Maternal IL-17A in autism.

6. Th22 cells induce Müller cell activation via the Act1/TRAF6 pathway in diabetic retinopathy.

Review 7. The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis.

8. Lumican negatively controls the pathogenicity of murine encephalitic TH17 cells.

9. EZH2 Mediates miR-146a-5p/HIF-1α to Alleviate Inflammation and Glycolysis after Acute Spinal Cord Injury.

Review 10. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?